• Reported GAAP EPS of $0.09 down -81.25% YoY • Reported revenue of $1.18B up 13.03% YoY • Auna reaffirms full-year revenue and Adjusted EBITDA guidance, expecting limited growth in the first and second quarters of 2026. The company remains confident in delivering its full-year Adjusted EBITDA range.
Bullish
Auna achieved strong commercial momentum with 13% revenue growth and 48% operating cash flow increase, driven by Mexico's oncology growth and Colombia's payor diversification.
Bearish
Auna's Adjusted EBITDA and Net Income declined due to lower margins, increased finance costs from FX losses, and S/14 million in Peru revenue adjustments from payor penalties.